Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial
- 24 November 2020
- journal article
- letter
- Published by Elsevier BV in American Heart Journal
- Vol. 233, 1-4
- https://doi.org/10.1016/j.ahj.2020.11.003
Abstract
No abstract availableFunding Information
- Merck
- Amgen
- Novartis
- Bristol-Myers Squibb
- Duke Clinical Research Institute
- Heart Failure Society of America
- American Heart Association
- AstraZeneca
This publication has 8 references indexed in Scilit:
- Body surface area and medication dosing in patients with heart failure with reduced ejection fractionTrends in Cardiovascular Medicine, 2020
- Titration of Medical Therapy for Heart Failure With Reduced Ejection FractionJournal of the American College of Cardiology, 2019
- Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism anglePharmacogenomics, 2018
- 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection FractionJournal of the American College of Cardiology, 2018
- Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart FailureCirculation: Heart Failure, 2017
- Factors Related to Morbidity and Mortality in Patients With Chronic Heart Failure With Systolic DysfunctionCirculation: Heart Failure, 2012
- Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION): Design and rationaleAmerican Heart Journal, 2007
- Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart FailureCirculation, 1996